Get informed when a big investor buys or sells
+ FollowOvervalued by 67.5% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $4.04 Million |
|---|---|
| Enterprise Value | $3.42 Million |
| Earnings per Share | $-2.2 |
| Beta | -1.03 |
| Outstanding Shares | 2,431,695 |
| P/E Ratio | -0.84 |
|---|---|
| PEG | 2.5 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1140.54 |
| Enterprise Value to EBIT | -0.93 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 3.15%▼ 0.57% |
|---|---|
| Total Invested | $67,941▼ 66.78% |
| Investors Holding | 21▼ 9.00% |
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled int...